SynthesisFrontiers in immunology2026
The spectrum of bleeding in Wiskott-Aldrich syndrome: a systematic review and meta-analysis of incidence and mortality.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bleeding is the predominant clinical manifestation and one of the leading causes of death of Wiskott-Aldrich syndrome (WAS). However, significant discrepancies in reported bleeding phenotypes persist. Objective: This systematic review and meta-analysis aim to provide a comprehensive characterization of the bleeding phenotype and elucidate the resultant mortality burden among patients with WAS. Methods: Observational studies reporting either the cumulative incidence of bleeding manifestations or the occurrence of fatal hemorrhagic events in patients with WAS were included. The Joanna Briggs Institute critical appraisal tool was used to assess the risk of bias. A generalized linear mixed model with a binomial-normal distribution was employed for the meta-analysis. Subgroup analyses, stratified by clinical stage at data collection, and meta-regression analyses were conducted to explore heterogeneity. Results: A total of 40 studies involving 1865 patients were identified. The pooled cumulative incidences of overall and site-specific bleeding (excluding gastrointestinal bleeding), increased significantly from disease onset to diagnosis and through to the end of follow-up. At the end of follow-up, the pooled cumulative incidence of multisystem bleeding and severe bleeding was 57% (95% CI 41-72) and 19% (95% CI 12-28), respectively. Both sample size and proportion of patients with a WAS score of 5 were associated with cumulative incidence of severe bleeding at the end of follow-up ( Conclusions: Bleeding complications are nearly universal and progressive in patients with WAS. Given that most fatal hemorrhages occur in early childhood and curative treatment significantly mitigates this risk, prompt implementation of such therapy is imperative. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261277891.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.